Table 2 Compare of clinicopathologic features and mutational profile by the presence of metastasis in clear cell RCC
Localized N = 12 | Metastatic N = 8 | p-value | |
|---|---|---|---|
Age | 61.4 ± 12.7 | 66.9 ± 8.6 | 0.303 |
Sex – male (%) | 8 (66.7%) | 5 (62.5%) | 1.000‡ |
BMI (kg/m2) | 25.7 ± 4.3 | 23.8 ± 6.3 | 0.439 |
DM | 8 (66.7%) | 6 (75.0%) | 1.000‡ |
HTN | 5 (41.7%) | 3 (37.5%) | 1.000‡ |
Mass size (cm) | 5.8 ± 2.0 | 8.8 ± 2.4 | 0.008 |
Pathologic T stage – N (%) | 0.071※ | ||
< T2 | 0 (0%) | 2 (25.0%) | |
T3 | 12 (100%) | 5 (62.5%) | |
T4 | 0 (0%) | 1 (12.55) | |
Tumor thrombus level– N (%) | 0.225※ | ||
Level 0 | 10 (83.3%) | 5 (62.5%) | |
Level 1 | 1 (8.3%) | 3 (37.5%) | |
Level 2 | 1 (8.3%) | 0 (0%) | |
Fuhrman grade | 0.400‡ | ||
3 | 12 (100%) | 4 (87.5%) | |
4 | 0 (0%) | 1 (12.5%) | |
Lymphovascular invasion | 2 (16.7%) | 4 (50.0%) | 0.161‡ |
Mutation Counts | 7.0 ± 3.2 | 7.1 ± 2.9 | 0.930 |
VHL | 9 (75.0%) | 5 (62.5%) | 0.642‡ |
PBRM1 | 2 (16.7%) | 5 (62.5%) | 0.062‡ |
NOTCH4 | 4 (33.3%) | 1 (12.5%) | 0.603‡ |
KMT2D | 1 (8.3%) | 1 (12.5%) | 1.000‡ |
NOTCH3 | 2 (16.7%) | 1 (12.5%) | 1.000‡ |
TSC1 | 3 (25.0%) | 1 (12.5%) | 0.619 |
BAP1 | 5 (41.7%) | 2 (25.0%) | 0.642‡ |
BRCA2 | 2 (16.7%) | 0 (0%) | 0.495‡ |
SETD2 | 0 (0%) | 1 (12.5%) | 0.400‡ |